ArticleClinical journal of gastroenterology2025
A case of relapsed pan-colonic ulcerative colitis accompanied with gastroduodenal lesions immediately after COVID-19.
Article in Clinical journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diffuse duodenitis in a patient with ulcerative colitis who was successfully treated with upadacitinib.Clinical journal of gastroenterology · 2026Article
- A Rare Case of Small Bowel Ulceration Induced by COVID-19.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Some patients with ulcerative colitis (UC) suffer from complicated UC-associated upper gastrointestinal lesions. However, the trigger of these lesions has not been clarified. Herein, we present a 28-year-old man with relapsed pan-colonic UC accompanied by gastroduodenal lesions immediately after contracting coronavirus disease 2019 (COVID-19). In this patient, UC relapsed approximately 7 days after the COVID-19 onset, despite being in remission for 3 years. The patient also developed symptoms such as epigastric pain and nausea on day 19 of COVID-19. The endoscopic and pathologic findings of the stomach and duodenum closely resembled colorectal lesions of UC; accordingly, we diagnosed the patient with UC-associated gastroduodenal lesions. Corticosteroids were significantly effective in the colorectal and upper gastrointestinal lesions, leading to remission. This report is the first to describe UC-associated upper GI lesions that developed right after COVID-19 infection. Therefore, COVID-19 can be a possible trigger of UC-associated upper gastrointestinal lesion. Further studies are needed to understand the relationship between the onset of UC or UC-associated upper GI lesions and COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.